CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Tamoxifen +1 moredrug
Likely dose
Tamoxifen 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03528902
NCT03528902Phase 2Completed
CompareCT.gov

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

Vanderbilt University Medical Center·interventional·Posted May 18, 2018·Updated Dec 5, 2024

In Brief

A Phase 2 clinical trial evaluating Tamoxifen and Placebo Oral Tablet for Hypertension and 8 related conditions. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The main purpose of this clinical trial is to examine the feasibility and effects of tamoxifen in subjects with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated, and its impact on functional condition and selected biomarkers. Changes in tricuspid annular plane systolic excursion (TAPSE) and other parameters determined by transthoracic echocardiography will be evaluated as well as changes in additional metrics such as six minute walk test distance, quality of life assessments, and hormone levels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Tamoxifen, Estrogen Receptor Antagonist, Hormone Antagonists, Estrogens
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 18, 2018
Enrollment StartOct 1, 2018
Primary CompletionJun 14, 2023
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 8.1 years ago

Interventions

Tamoxifendrug

Tamoxifen 20 mg po daily for 24 weeks.

Placebo Oral Tabletdrug

Placebo